Skip to Content

Wakix (pitolisant) Disease Interactions

There are 5 disease interactions with Wakix (pitolisant):

Major

Pitolisant (applies to Wakix) hepatic impairment

Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Pitolisant is contraindicated in patients with severe hepatic impairment. Pitolisant is extensively metabolized by the liver. Care should be exercised when using pitolisant in patients with moderate hepatic impairment. It is recommended to monitor patients with mild and moderate hepatic impairment and to adjust the dosage of pitolisant in patients with moderate hepatic impairment as appropriate. No dosage adjustment is recommended in patients with mild hepatic impairment.

Moderate

CNS stimulants (applies to Wakix) bipolar disorders

Moderate Potential Hazard, Moderate plausibility.

Central nervous system (CNS) stimulants may induce a mixed/manic episode in patients with bipolar disorder. Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression). Close monitoring is recommended when using these agents in patients with bipolar disorders.

Moderate

CNS stimulants (applies to Wakix) psychotic disorders

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Psychosis

Central nervous system (CNS) stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder. Close monitoring is recommended when using these agents in patients with psychotic disorders.

Moderate

Pitolisant (applies to Wakix) arrhythmias

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease, Renal Dysfunction, Hypokalemia, Magnesium Imbalance

Pitolisant prolongs the QT interval. The use of pitolisant should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval. The use of pitolisant should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and the presence of congenital prolongation of the QT interval. The risk of QT prolongation may be greater in patients with hepatic or renal impairment due to higher concentrations of pitolisant. It is recommended to monitor patients with hepatic or renal impairment for increased QTc. Exercise care when using this agent in patients with these conditions.

Moderate

Pitolisant (applies to Wakix) renal disease

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

The pharmacokinetics of pitolisant in patients with end-stage renal disease (ESRD) (eGFR of <15 mL/minute/1.73 m2) is unknown. Pitolisant is not recommended in patients with ESRD. It is recommended to adjust the dosage of pitolisant when using this agent in patients with moderate (eGFR 30 to 59 mL/minute/1.73 m2) and severe (eGFR 15 to 29 mL/minute/1.73 m2) renal impairment.

Wakix (pitolisant) drug interactions

There are 419 drug interactions with Wakix (pitolisant)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.